TransMedics Financials

TMDX Stock  USD 69.05  0.21  0.31%   
Based on the key indicators related to TransMedics' liquidity, profitability, solvency, and operating efficiency, TransMedics Group may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, TransMedics' Property Plant Equipment is fairly stable compared to the past year. Other Current Liabilities is likely to rise to about 47.4 M in 2025, whereas Other Liabilities is likely to drop slightly above 901.6 K in 2025. Key indicators impacting TransMedics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio5.668.299
Way Down
Slightly volatile
The essential information of the day-to-day investment outlook for TransMedics includes many different criteria found on its balance sheet. An individual investor should monitor TransMedics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in TransMedics.

Net Income

37.24 Million

  

TransMedics Group Earnings Geography

Please note, the imprecision that can be found in TransMedics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of TransMedics Group. Check TransMedics' Beneish M Score to see the likelihood of TransMedics' management manipulating its earnings.

TransMedics Stock Summary

TransMedics competes with Inspire Medical, InMode, Insulet, Pulmonx Corp, and Orthofix Medical. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company was founded in 1998 and is headquartered in Andover, Massachusetts. Transmedics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 148 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS89377M1099
CUSIP89377M109
LocationMassachusetts; U.S.A
Business Address200 Minuteman Road,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.transmedics.com
Phone(978) 552 0900
CurrencyUSD - US Dollar

TransMedics Key Financial Ratios

TransMedics Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets152.0M134.9M277.1M706.0M804.1M844.3M
Net Tangible Assets54.6M103.9M67.9M187.4M215.5M226.3M
Retained Earnings(398.2M)(442.4M)(478.7M)(503.7M)(468.2M)(491.7M)
Accounts Payable1.2M6.7M3.3M12.7M10.3M6.0M
Cash24.6M25.6M201.2M394.8M336.7M353.5M
Long Term Debt34.7M35.2M58.7M506.2M509.3M534.8M
Inventory11.9M14.9M20.6M44.2M46.6M48.9M
Total Liab48.1M67.0M89.8M568.8M575.5M604.2M
Total Current Assets146.8M118.7M252.3M510.7M497.2M522.1M
Common Stock502.2M510.5M666.3M641.1M697.2M415.0M
Other Current Liab10.4M16.3M17.2M38.2M45.2M47.4M
Net Receivables6.9M5.9M27.6M63.6M97.7M102.6M
Net Debt10.1M(17.0M)(133.6M)121.1M122.3M128.4M
Long Term Debt Total33.7M34.1M34.7M35.2M40.5M31.8M
Other Current Assets4.7M5.5M2.9M8.0M16.3M17.1M
Net Invested Capital138.5M103.1M246.1M643.4M737.9M774.8M
Net Working Capital134.9M95.5M228.6M455.7M437.3M459.2M
Capital Stock502.2M510.5M666.3M641.1M697.2M592.8M

TransMedics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
202020212022202320242025 (projected)
Interest Expense4.0M3.9M3.7M10.8M14.4M15.1M
Operating Income(26.4M)(39.4M)(31.4M)(28.7M)37.5M39.4M
Ebit(24.7M)(41.1M)(33.2M)(15.8M)50.2M52.7M
Research Development18.8M22.3M26.8M63.3M56.0M29.1M
Income Before Tax(28.7M)(44.2M)(36.2M)(26.7M)35.8M37.6M
Net Income(28.7M)(44.2M)(36.2M)(25.0M)35.5M37.2M
Net Interest Income(4.0M)(3.9M)(3.7M)(8.2M)(14.4M)(13.7M)
Total Revenue25.6M30.3M93.5M241.6M441.5M463.6M
Gross Profit16.6M21.2M65.3M154.1M262.1M275.2M
Ebitda(23.2M)(38.5M)(29.0M)(7.6M)69.9M73.4M
Cost Of Revenue9.0M9.1M28.2M87.5M179.5M188.4M

TransMedics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of TransMedics Group. It measures of how well TransMedics is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money TransMedics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money TransMedics had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what TransMedics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
202020212022202320242025 (projected)
Change To Inventory(1.7M)(4.9M)(8.0M)(28.1M)(8.4M)(8.8M)
Investments(41.1M)32.8M54.5M(154.9M)(129.3M)(122.8M)
Change In Cash4.5M999K175.6M193.6M(58.2M)(55.3M)
Depreciation1.6M1.8M3.5M8.2M19.8M20.7M
Capital Expenditures455K3.5M11.9M179.1M129.7M136.2M
Net Income(28.7M)(44.2M)(36.2M)(25.0M)35.5M37.2M
End Period Cash Flow25.1M26.1M201.7M395.3M337.2M354.0M
Change To Netincome1.7M2.5M7.8M13.7M15.7M16.5M
Free Cash Flow(30.7M)(32.4M)(57.7M)(192.1M)48.8M51.2M
Other Non Cash Items511K1.4M3.4M30.0M48.8M51.2M

TransMedics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining TransMedics's current stock value. Our valuation model uses many indicators to compare TransMedics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across TransMedics competition to find correlations between indicators driving TransMedics's intrinsic value. More Info.
TransMedics Group is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers reporting about  0.16  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for TransMedics Group is roughly  6.25 . At this time, TransMedics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the TransMedics' earnings, one of the primary drivers of an investment's value.

TransMedics' Earnings Breakdown by Geography

TransMedics Group Systematic Risk

TransMedics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. TransMedics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on TransMedics Group correlated with the market. If Beta is less than 0 TransMedics generally moves in the opposite direction as compared to the market. If TransMedics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one TransMedics Group is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of TransMedics is generally in the same direction as the market. If Beta > 1 TransMedics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in TransMedics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various TransMedics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of TransMedics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.23)

At this time, TransMedics' Price Earnings To Growth Ratio is fairly stable compared to the past year.

TransMedics March 22, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of TransMedics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of TransMedics Group. We use our internally-developed statistical techniques to arrive at the intrinsic value of TransMedics Group based on widely used predictive technical indicators. In general, we focus on analyzing TransMedics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build TransMedics's daily price indicators and compare them against related drivers.

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.